FDA Approves Invokana (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes and DKD

RARITAN, N.J., Sept. 30, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a new indication for Invokana (canagliflozin) to reduce the risk of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news